Week In Review: Zai Lab Enters $338 Million Agreement To In-License KRAS Inhibitor

Shanghai's Zai Lab in-licensed Greater China rights to adagrasib, a KRASG12C inhibitor, from Mirati of San Diego in a $338 million agreement. Mirati will receive a $65 million upfront payment and up to $273 million in milestones, plus royalties.